Svp, Senior Credit Analyst And Deputy Director Of Us Credit Research
CurrentPrimary analyst covering high yield issuers in the health care sector, including facilities, pharmaceuticals and insurance companies. This sector represents approximately over 10% of Amundi US’s leveraged credit investments. Coverage primarily consists of high yield bonds, convertible bonds, and leveraged loans. Additional coverage includes IG and EM corporates and SMID leveraged equities. Experienced in hard asset, real estate, and distressed valuation.As deputy director of US credit research, develop and mentor internal talent and help recruit externally. Also, lead the bottoms-up (analyst-driven) sector positioning framework across all US high yield funds.Healthcare security selection contribution to excess returns for primary US high yield fund-- 2019: +118 bps; 2020: +23 bps; 2021: +0 bps; 2022: +16 bps; 2023: +11 bps; YTD 2024 through April: +28 bps. Previous coverage also included diversified media, broadcasters and food & beverage, with long-term excess performance in each.